Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications.
Adelaiye R, Ciamporcero E, Miles KM, Sotomayor P, Bard J, Tsompana M, Conroy D, Shen L, Ramakrishnan S, Ku SY, Orillion A, Prey J, Fetterly G, Buck M, Chintala S, Bjarnason GA, Pili R. Adelaiye R, et al. Mol Cancer Ther. 2015 Feb;14(2):513-22. doi: 10.1158/1535-7163.MCT-14-0208. Epub 2014 Dec 17. Mol Cancer Ther. 2015. PMID: 25519701 Free PMC article.
YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage.
Ciamporcero E, Shen H, Ramakrishnan S, Yu Ku S, Chintala S, Shen L, Adelaiye R, Miles KM, Ullio C, Pizzimenti S, Daga M, Azabdaftari G, Attwood K, Johnson C, Zhang J, Barrera G, Pili R. Ciamporcero E, et al. Among authors: adelaiye r. Oncogene. 2016 Mar 24;35(12):1541-53. doi: 10.1038/onc.2015.219. Epub 2015 Jun 29. Oncogene. 2016. PMID: 26119935 Free PMC article.
Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial.
Pili R, Liu G, Chintala S, Verheul H, Rehman S, Attwood K, Lodge MA, Wahl R, Martin JI, Miles KM, Paesante S, Adelaiye R, Godoy A, King S, Zwiebel J, Carducci MA. Pili R, et al. Among authors: adelaiye r. Br J Cancer. 2017 Mar 28;116(7):874-883. doi: 10.1038/bjc.2017.33. Epub 2017 Feb 21. Br J Cancer. 2017. PMID: 28222071 Free PMC article. Clinical Trial.
Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models.
Shen L, Sundstedt A, Ciesielski M, Miles KM, Celander M, Adelaiye R, Orillion A, Ciamporcero E, Ramakrishnan S, Ellis L, Fenstermaker R, Abrams SI, Eriksson H, Leanderson T, Olsson A, Pili R. Shen L, et al. Among authors: adelaiye r. Cancer Immunol Res. 2015 Feb;3(2):136-48. doi: 10.1158/2326-6066.CIR-14-0036. Epub 2014 Nov 4. Cancer Immunol Res. 2015. PMID: 25370534 Free PMC article.
14 results